Tern Plc Mathew Scherba seconded to Konektio

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has agreed with the board of InVMA Limited, trading as Konektio, of which Tern currently owns 36.8% of the equity, and Konektio’s other investors, that Mathew Scherba, a director of Tern, will join the Konektio executive team for an initial two month period, with an option, on the mutual agreement of both parties, to further extend the secondment, to assist with the development of the Konektio business.

Mathew Scherba, will remain a director of Tern, fulfilling his duties and responsibilities at Tern, but will devote the majority of his time to assisting Konektio as it executes its growth plans, in particular the completion of the productisation of the next release of AssetMinder®, its modular, industry 4.0, IoT (software as a service) SaaS platform.  The agreement for Mr Scherba’s services will see Tern receive payments from Konektio, equal to the basic salary he is paid by Tern for the time he commits to Konektio.

Commenting Al Sisto, CEO of Tern, said:

“Tern’s hands-on approach with its portfolio companies is key to creating further value so that Tern shareholders can ultimately benefit from this value.  We are therefore pleased, with the agreement and support of Konektio’s other investors, to be able to provide Konektio with the benefit of Mathew Scherba’s skills and experience to help drive the completion of the productisation of their next exciting release of AssetMinder® and further expand their routes to market.

“All of the team at Tern continue to focus, in a hands-on manner, on maximising the investment value for Tern shareholders from our portfolio companies and I look forward to making further announcements on their progress in due course.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Search